Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy

Autor: Sungjin Kim, Sarah Walcott-Sapp, Marissa K. Srour, Minna K Lee, Armando E. Giuliano, Alice P. Chung, Srivarshini Cherukupalli Mohan, Farin Amersi
Rok vydání: 2021
Předmět:
Zdroj: Annals of Surgical Oncology. 28:5907-5917
ISSN: 1534-4681
1068-9265
Popis: Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS). A total of 303 patients treated with NAT from 2008 to 2016 were identified from a prospective database. Biomarker status at diagnosis was determined and retested after NAT in patients with RD. DFS and OS were compared among three groups: no biomarker change, clinically insignificant change in either ER or PR without alteration in HR status, and clinically significant change in at least one biomarker with resultant change in HR or HER2 status. Subgroups with no change and HR change were examined [HR+HER2− no change, triple negative (TN) no change, HR+HER2− to TN, TN to HR+HER2]. Overall, 61.4% of patients had RD. Of these, 32.8% had changes in at least one biomarker. At median follow up of 5.48 years, no biomarker change was associated with improved DFS compared with changes in HR or HER2 status (p = 0.043). In addition, no biomarker change (p = 0.005) and clinically insignificant changes in biomarker status (p = 0.019) were associated with improved OS compared with clinically significant changes in HR or HER2 status. Among subgroups, HR+HER2− to TN was associated with worse DFS (p = 0.029) and OS (p = 0.008) compared with HR+HER2− no change. Among those with RD, biomarker status change was common and impacted survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications.
Databáze: OpenAIRE
Externí odkaz: